Until comprehensive carcinogenicity studies are completed, individuals with active cancer, cancer history, or high genetic cancer risk should avoid BPC-157
PCAC review (July 2026) The FDA stated it intends to consult the Pharmacy Compounding Advisory Committee on July 23, 2026 regarding inclusion of BPC-157 acetate and BPC-157 (free base) on the 503A bulks list
While the study reported improved healing, only BPC-157 appeared to have exhibited consistent results in all wound types (i.e., chronic and acute) on the esophagus, stomach, duodenum, and lower GI tract
Why cycling matters Cycling, alternating periods of use with periods off, maintains the peptide's effectiveness and reduces potential risks
This context-dependent behavior aligns with the peptides overall pattern of normalizing tissue function rather than simply stimulating growth